133 related articles for article (PubMed ID: 8479168)
1. Phorbol dibutyrate and ionomycin improve murine effector cell cytotoxicity.
Hamby LS; Freeman JW; McGrath PC
J Surg Res; 1993 Feb; 54(2):115-21. PubMed ID: 8479168
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of adoptive immunotherapy: improved methods for in vivo tracking of tumor-infiltrating lymphocytes and lymphokine-activated killer cells.
Wallace PK; Palmer LD; Perry-Lalley D; Bolton ES; Alexander RB; Horan PK; Yang JC; Muirhead KA
Cancer Res; 1993 May; 53(10 Suppl):2358-67. PubMed ID: 8485722
[TBL] [Abstract][Full Text] [Related]
3. Alteration of human lymphokine-activated killer cell activity by manipulation of protein kinase C and cytosolic Ca2+.
McCrady CW; Li F; Grant AJ; Merchant RE; Carchman RA
Cancer Res; 1988 Feb; 48(3):635-40. PubMed ID: 3257170
[TBL] [Abstract][Full Text] [Related]
4. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
5. Activation and growth of murine tumor-specific T-cells which have in vivo activity with bryostatin 1.
Tuttle TM; Inge TH; Bethke KP; McCrady CW; Pettit GR; Bear HD
Cancer Res; 1992 Feb; 52(3):548-53. PubMed ID: 1732041
[TBL] [Abstract][Full Text] [Related]
6. Murine studies using polyethylene glycol-modified recombinant human interleukin 2 (PEG-IL-2): antitumor effects of PEG-IL2 alone and in combination with adoptive cellular transfer.
Yang JC; Schwarz SL; Perry-Lalley DM; Rosenberg SA
Lymphokine Cytokine Res; 1991 Dec; 10(6):475-80. PubMed ID: 1804310
[TBL] [Abstract][Full Text] [Related]
7. Phorbol dibutyrate plus ionomycin improves the generation of cytotoxic T cells from draining lymph nodes of patients with advanced head and neck cancer.
McGrath PC; Hamby LS; Freeman JW
Am J Surg; 1992 Dec; 164(6):610-4. PubMed ID: 1463110
[TBL] [Abstract][Full Text] [Related]
8. Solid-phase anti-CD3 antibody activation of murine tumor-infiltrating lymphocytes.
Massaro AF; Schoof DD; Rubinstein A; Zuber M; Leonard-Vidal FJ; Eberlein TJ
Cancer Res; 1990 May; 50(9):2587-92. PubMed ID: 2139356
[TBL] [Abstract][Full Text] [Related]
9. [Adoptive immunotherapy and metastasized cancer of the kidney. Regulator effects of interleukin-4 on tumor infiltrating lymphocytes (TIL)].
Peyret C; Bochner B; Lee TY; Tso CL; Dekernion JB; Belldegrun A
Chirurgie; 1991; 117(9):700-9. PubMed ID: 1843670
[TBL] [Abstract][Full Text] [Related]
10. Activation of CD8+ murine T cells from tumor-draining lymph nodes by phorbol dibutyrate plus calcium ionophore.
Tuttle TM; Inge TH; McCrady CM; Bethke KP; Bear HD
J Immunother (1991); 1992 Jul; 12(1):32-40. PubMed ID: 1386251
[TBL] [Abstract][Full Text] [Related]
11. Immunosensitization of resistant human tumor cells to cytotoxicity by tumor infiltrating lymphocytes.
Frost P; Caliliw R; Belldegrun A; Bonavida B
Int J Oncol; 2003 Feb; 22(2):431-7. PubMed ID: 12527945
[TBL] [Abstract][Full Text] [Related]
12. Induction of tumoricidal activity and alterations of growth by interleukin-2 and manipulation of protein kinase C and cytosolic calcium in childhood acute lymphocytic leukemia cells.
Massey GV; McCrady CW; Dunn NL; Russell EC; Carchman RA
Leukemia; 1989 Aug; 3(8):602-10. PubMed ID: 2787455
[TBL] [Abstract][Full Text] [Related]
13. Precursor frequency analysis of bryostatin activated lymphocytes.
Fleming MD; Barrett SK; Bear HD
J Surg Res; 1994 Jul; 57(1):74-9. PubMed ID: 8041153
[TBL] [Abstract][Full Text] [Related]
14. [Comparative study of the functional expression of the Na/K-pump in human lymphocytes, activated by phytohemagglutinin, phorbol ester, ionomycin, and interleukin-2].
Toropova FV; Vinogradova TA; Marakhova II
Tsitologiia; 2001; 43(2):148-55. PubMed ID: 11347470
[TBL] [Abstract][Full Text] [Related]
15. Phenotypical and functional differences of tumor-infiltrating lymphocytes from human colorectal cancers induced by costimulation with rIL-2 and rIL-4 in vitro.
Keller H; Wimmenauer S; Rahner S; Von Kleist S; Farthmann EH
Anticancer Res; 1996; 16(6B):3565-70. PubMed ID: 9042222
[TBL] [Abstract][Full Text] [Related]
16. Immunosensitization of prostate carcinoma cell lines for lymphocytes (CTL, TIL, LAK)-mediated apoptosis via the Fas-Fas-ligand pathway of cytotoxicity.
Frost P; Ng CP; Belldegrun A; Bonavida B
Cell Immunol; 1997 Aug; 180(1):70-83. PubMed ID: 9316641
[TBL] [Abstract][Full Text] [Related]
17. TNF-alpha potentiation of the lymphokine-activated killer response of murine thymus cells.
Ujházy P; Maccubbin D; Eppolito C; Mihich E; Ehrke MJ
Lymphokine Cytokine Res; 1994 Apr; 13(2):99-106. PubMed ID: 8061121
[TBL] [Abstract][Full Text] [Related]
18. Postoperative immunotherapy for patients with hepatocarcinoma using tumor-infiltrating lymphocytes.
Wang Y; Chen H; Wu M; Bao J; Cong W; Wang H
Chin Med J (Engl); 1997 Feb; 110(2):114-7. PubMed ID: 9594281
[TBL] [Abstract][Full Text] [Related]
19. Tumor-infiltrating lymphocytes cultured in recombinant interleukin-2: enhancement of growth, cytotoxicity, and phenotypic expression of cytotoxic T-cell antigens by cyclophosphamide given intravenously prior to tumor harvest.
Lafreniere R; Borkenhagen K; Bryant LD; Ng E
J Biol Response Mod; 1989 Jun; 8(3):238-51. PubMed ID: 2787392
[TBL] [Abstract][Full Text] [Related]
20. Enhanced cytolytic activity of tumor infiltrating lymphocytes (TILs) derived from an ICAM-1 transfected tumor in a murine model.
Lefor AT; Fabian DF
J Surg Res; 1998 Feb; 75(1):49-53. PubMed ID: 9614856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
